Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNgamma expression and macrophage activation during IFNbeta-1a treatment. Predose levels of beta2-MG increased, the significance of which is as yet unclear.
A one-year study on the pharmacodynamic profile of interferon-beta1a in MS / Bagnato, F; Pozzilli, Carlo; Scagnolari, Carolina; Bellomi, F; Pasqualetti, P; Gasperini, C; Millefiorini, Enrico; Galgani, S; Spadaro, M; Antonelli, Guido. - In: NEUROLOGY. - ISSN 0028-3878. - STAMPA. - 58 (9):(2002), pp. 1409-1411.
A one-year study on the pharmacodynamic profile of interferon-beta1a in MS
POZZILLI, Carlo;SCAGNOLARI, CAROLINA;PASQUALETTI P;MILLEFIORINI, Enrico;ANTONELLI, Guido
2002
Abstract
Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNgamma expression and macrophage activation during IFNbeta-1a treatment. Predose levels of beta2-MG increased, the significance of which is as yet unclear.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
